Cargando…

Potential utility of risk stratification for multicancer screening with liquid biopsy tests

Our proof-of-concept study reveals the potential of risk stratification by the combined effects of age, polygenic risk scores (PRS), and non-genetic risk factors in increasing the risk-benefit balance of rapidly emerging non-invasive multicancer early detection (MCED) liquid biopsy tests. We develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Elle S., Scharpf, Robert B., Garcia-Closas, Montserrat, Visvanathan, Kala, Velculescu, Victor E., Chatterjee, Nilanjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122653/
https://www.ncbi.nlm.nih.gov/pubmed/37087533
http://dx.doi.org/10.1038/s41698-023-00377-w
_version_ 1785029539007561728
author Kim, Elle S.
Scharpf, Robert B.
Garcia-Closas, Montserrat
Visvanathan, Kala
Velculescu, Victor E.
Chatterjee, Nilanjan
author_facet Kim, Elle S.
Scharpf, Robert B.
Garcia-Closas, Montserrat
Visvanathan, Kala
Velculescu, Victor E.
Chatterjee, Nilanjan
author_sort Kim, Elle S.
collection PubMed
description Our proof-of-concept study reveals the potential of risk stratification by the combined effects of age, polygenic risk scores (PRS), and non-genetic risk factors in increasing the risk-benefit balance of rapidly emerging non-invasive multicancer early detection (MCED) liquid biopsy tests. We develop and validate sex-specific pan-cancer risk scores (PCRSs), defined by the combination of body mass index, smoking, family history of cancers, and cancer-specific polygenic risk scores (PRSs), to predict the absolute risk of developing at least one of the many common cancer types. We demonstrate the added value of PRSs in improving the predictive performance of the risk factors only model and project the positive and negative predictive values for two promising multicancer screening tests across risk strata defined by age and PCRS.
format Online
Article
Text
id pubmed-10122653
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-101226532023-04-24 Potential utility of risk stratification for multicancer screening with liquid biopsy tests Kim, Elle S. Scharpf, Robert B. Garcia-Closas, Montserrat Visvanathan, Kala Velculescu, Victor E. Chatterjee, Nilanjan NPJ Precis Oncol Brief Communication Our proof-of-concept study reveals the potential of risk stratification by the combined effects of age, polygenic risk scores (PRS), and non-genetic risk factors in increasing the risk-benefit balance of rapidly emerging non-invasive multicancer early detection (MCED) liquid biopsy tests. We develop and validate sex-specific pan-cancer risk scores (PCRSs), defined by the combination of body mass index, smoking, family history of cancers, and cancer-specific polygenic risk scores (PRSs), to predict the absolute risk of developing at least one of the many common cancer types. We demonstrate the added value of PRSs in improving the predictive performance of the risk factors only model and project the positive and negative predictive values for two promising multicancer screening tests across risk strata defined by age and PCRS. Nature Publishing Group UK 2023-04-22 /pmc/articles/PMC10122653/ /pubmed/37087533 http://dx.doi.org/10.1038/s41698-023-00377-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Kim, Elle S.
Scharpf, Robert B.
Garcia-Closas, Montserrat
Visvanathan, Kala
Velculescu, Victor E.
Chatterjee, Nilanjan
Potential utility of risk stratification for multicancer screening with liquid biopsy tests
title Potential utility of risk stratification for multicancer screening with liquid biopsy tests
title_full Potential utility of risk stratification for multicancer screening with liquid biopsy tests
title_fullStr Potential utility of risk stratification for multicancer screening with liquid biopsy tests
title_full_unstemmed Potential utility of risk stratification for multicancer screening with liquid biopsy tests
title_short Potential utility of risk stratification for multicancer screening with liquid biopsy tests
title_sort potential utility of risk stratification for multicancer screening with liquid biopsy tests
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122653/
https://www.ncbi.nlm.nih.gov/pubmed/37087533
http://dx.doi.org/10.1038/s41698-023-00377-w
work_keys_str_mv AT kimelles potentialutilityofriskstratificationformulticancerscreeningwithliquidbiopsytests
AT scharpfrobertb potentialutilityofriskstratificationformulticancerscreeningwithliquidbiopsytests
AT garciaclosasmontserrat potentialutilityofriskstratificationformulticancerscreeningwithliquidbiopsytests
AT visvanathankala potentialutilityofriskstratificationformulticancerscreeningwithliquidbiopsytests
AT velculescuvictore potentialutilityofriskstratificationformulticancerscreeningwithliquidbiopsytests
AT chatterjeenilanjan potentialutilityofriskstratificationformulticancerscreeningwithliquidbiopsytests